Astrana Health, Inc. (ASTH)
(Delayed Data from NSDQ)
$48.12 USD
+0.19 (0.40%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $48.67 +0.55 (1.14%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
ASTH 48.12 +0.19(0.40%)
Will ASTH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ASTH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ASTH
Astrana Health, Inc. (ASTH) Q2 Earnings and Revenues Beat Estimates
OPCH vs. ASTH: Which Stock Is the Better Value Option?
ASTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate RadNet (RDNT) to Report a Decline in Earnings: What to Look Out for
Astrana Health, Inc. (ASTH) Reports Next Week: Wall Street Expects Earnings Growth
Amedisys (AMED) Q2 Earnings and Revenues Top Estimates
Other News for ASTH
Astrana Health, Inc. to Participate in Upcoming Investor Conferences
Astrana Health price target raised by $13 at Baird, here's why
Diamond Hill Small Cap Composite Fund Q2 2024 Market Commentary
Astrana Health price target raised by $9 at Truist, here's why
Bank of America Securities Reaffirms Their Buy Rating on Astrana Health (ASTH)